About Us
Explore how nanobubble innovation is driving breakthroughs in cancer diagnosis and precision therapy.
About Us
Explore how nanobubble innovation is driving breakthroughs in cancer diagnosis and precision therapy.
Contrast media improves image quality in all diagnostic applications. Ultrasound has lagged behind.
Visano harnesses the power of nanomedicine and sound to bring precise
cancer diagnosis and theranostic potential to standard ultrasound technology. The new contrast media can target specific cell biomarkers, works for small parts, high frequency imaging modes and provides ondemand cavitation for drug-free treatment.
What We Do
Ultrasound imaging has the potential to provide life-saving diagnostic and therapeutic interventions to every patient. Unlike the resource-intensive MRI, PET, or CT technology, ultrasound is portable and cost effective yet exceptionally powerful.
Contrast media improves image quality in all diagnostic applications. Ultrasound has lagged behind.
Visano harnesses the power of nanomedicine and sound to bring precise
cancer diagnosis and theranostic potential to standard ultrasound technology. The new contrast media can target specific cell biomarkers, works for small parts, high frequency imaging modes and provides ondemand cavitation for drug-free treatment.
What We Do
Our mission is unlocking the full potential of ultrasound using a new type of contrast agent. With capability for cancer-specific accumulation and targeting biomarkers, the nanobubble technology brings molecular imaging to the forefront of ultrasound-based diagnosis. Noninvasive theranostic applications using the same platform can augment image-guided therapies and trigger potent immune reactions to help treat otherwise untreatable tumors.
Who We Are
With over 50 years of combined experience our founders bring expertise in molecular biology, nanomedicine, biomedical ultrasound, image-guided drug delivery and translation of technologies from bench to bedside.
Who We Are
With over 50 years of combined experience our founders bring expertise in molecular biology, nanomedicine, biomedical ultrasound, image-guided drug delivery and translation of technologies from bench to bedside.
James P. Basilion, Ph.D.
Inventor, Co-founder
Professor of Radiology & BME, CWRU
30+ years of experience in molecular oncology, translational tech
James P. Basilion, Ph.D.
Inventor, Co-founder
In addition to his primary roles, Dr. Basilion is actively engaged with various professional organizations, including the World Molecular Imaging Society and the Radiological Society of North America, where he continues to contribute to the advancement of medical imaging and cancer research. He is a Senior Member of the National Academy of Inventors, a Fellow of the World Molecular Imaging Society, and a Fellow of the National Foundation for Cancer Research.
Agata A. Exner, Ph.D.
Inventor, Co-founder
Professor of Radiology & BME, CWRU
20+ years of experience in imaging and nanomedicine
Agata A. Exner, Ph.D.
Inventor, Co-founder
Michael J. Haag, MS, MBA
Co-founder, Chief Executive Officer
20+ years of experience in technology commercialization.
Michael J. Haag, MS, MBA
Co-founder, Chief Executive Officer
During his tenure at CWRU, Michael led the re-establishment of Case Technology Ventures (CTV), later rebranded as The Spartan Fund, which he served as its Managing Director. The Spartan Fund became a vital pre-seed, evergreen venture fund designed to support early-stage, high-risk technologies from the university. Under Michael’s leadership, the Spartan Fund Catalyst Program, which provided $5,000 in consulting services to startups going through the diligence process was established. His work contributed to the growth and success of CWRU's entrepreneurial ecosystem, with over 80 start-ups launched, 10 of which were acquired and three exited through IPOs, collectively representing an exit value of more than $325 million.
In addition to his venture creation efforts, Michael secured approximately $3.5 million in commercialization grants as Principal Investigator and played an integral role in managing translational research programs, which invested over $2 million annually. His leadership in technology transfer resulted in over $40 million in total revenue for CWRU, including negotiating four of the largest up-front payments in the university’s history.
In 2023, Michael founded TherExel LLC, a technology commercialization consulting firm. This move reflects his ongoing passion for start-up creation and venture development. Throughout his career, Michael has cultivated a vast network of industry connections, including investors, entrepreneurs, and key stakeholders, which he leverages to drive innovation and partnerships. His dedication to translational research and venture creation has made him a highly respected figure in both the academic and business communities.
Michael holds an M.S. in biology from CWRU, an M.B.A. from the University of Phoenix, and a B.S. in Biology and Chemistry from John Carroll University. He is a member of the Licensing Executives Society and the Association of University Technology Managers.